Last reviewed · How we verify

Ab&B Bio-tech Co., Ltd.JS — Portfolio Competitive Intelligence Brief

Ab&B Bio-tech Co., Ltd.JS pipeline: 0 marketed, 0 filed, 2 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 2 Phase 3 2 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Quadrivalent influenza virus subunit vaccine Quadrivalent influenza virus subunit vaccine phase 3 Inactivated influenza vaccine Immunology
Quadrivalent split influenza virus vaccine Quadrivalent split influenza virus vaccine phase 3 Immunology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Assistance Publique - Hôpitaux de Paris · 1 shared drug class
  2. Brigham and Women's Hospital · 1 shared drug class
  3. Chiltern Pesquisa Clinica Ltda · 1 shared drug class
  4. Fluart Innovative Vaccine Ltd, Hungary · 1 shared drug class
  5. Folia Biotech Inc. · 1 shared drug class
  6. GlaxoSmithKline · 1 shared drug class
  7. Green Cross Corporation · 1 shared drug class
  8. Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Ab&B Bio-tech Co., Ltd.JS:

Cite this brief

Drug Landscape (2026). Ab&B Bio-tech Co., Ltd.JS — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/ab-b-bio-tech-co-ltd-js. Accessed 2026-06-10.

Related